Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation and Research (CBER), overseeing vaccines and cell and gene therapies.